UniQure (QURE) said Thursday the Independent Data Monitoring Committee for a phase 1/2 trial of AMT-162 to treat amyotrophic lateral sclerosis caused by mutations in the superoxide dismutase 1 gene recommended going ahead with enrollment in the second group after reviewing safety data from the first group in the study.
The committee's review didn't identify any "significant safety concerns," the company said, adding it plans to start enrollment of the second dose group in Q1 2025.
The trial is being conducted in the US and has three dose-escalating groups with up to four patients each getting a short course of immunosuppression before and after an intrathecal infusion of AMT-162, the company said.
Price: 15.27, Change: +0.03, Percent Change: +0.16
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。